On March 21, 2018, a Contract was signed at the Russian Federation Commercial Agency in Djakarta, Indonesia, on production of the medicinal product “Proanes” (International Non-proprietary Name - Propofol) in the dosage form - emulsion for intravenous administration based on the industrial facilities of the largest Indonesian pharmaceutical company PT SANBE FARMA. The medicinal product will be produced based on the Enterprise's technology. The product marketing authorisation holder and Proanes® (INN - Propofol) trade mark proprietor is FSUE Moscow Endocrine Plant.
The Contract was signed by the Director of FSUE Moscow Endocrine Plant, Mikhail Fonarev, and the owner of PT SANBE FARMA Company, doctor G. Santoso, in the presence of the ambassador of the Russian Federation in the Republic of Indonesia, Lyudmila Georgievna Vorobieva, the trade representative of Russia in the Republic of Indonesia, Sergey Yurievich Rossomakhov, and the special representative of the vice-president of the Chamber of Auditors of the Republic of Indonesia, Andkhar Prakaso.
The Contract was concluded for a term of two years from the moment of putting the emulsion production facility into operation based on Enterprise’s own capacities.
Comment type is not specified in the component properties.